Ovarian Cancer | Oncology Today with Dr Neil Love: Current and Future Treatment Strategies for Advanced Ovarian Cancer

published 5 months ago by Dr Neil Love

Featuring an interview with Dr Kathleen Moore on the following topics: Recent data with PARP inhibitors and immune checkpoint inhibitors for advanced ovarian cancer (0:00) Efficacy of lenvatinib alone and in combination with pembrolizumab in patients with previously treated ovarian cancer (34:23) Activity of mirvetuximab soravtansine alone and with bevacizumab in patients with ovarian cancer (36:23) Incidence of acute myeloid leukemia and myelodysplastic syndromes in the Phase III SOLO-2 trial assessing maintenance olaparib for patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation (39:30) Case: A woman in her early 40s with metastatic ovarian cancer and a BRCA1 mutation receives olaparib as maintenance therapy (44:25) Case: A woman in her late 40s develops anemia after receiving maintenance olaparib for advanced ovarian cancer with a BRCA mutation (54:24) Counseling patients with ovarian cancer about the side effects associated with PARP inhibitors (1:01:57) Integration of PARP inhibitors into the therapeutic algorithm for ovarian cancer (1:09:23) CME information and select publications

more episodes from Research To Practice | Oncology Videos